Literature DB >> 18278991

Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia.

Taishiro Kishimoto1, Koichiro Watanabe, Naoki Shimada, Kazuya Makita, Gohei Yagi, Haruo Kashima.   

Abstract

OBJECTIVE: An inhibitory effect of hyperprolactinemia on the hypothalamo-pituitary-gonadal axis has been suggested as a mechanism of bone loss in schizophrenia, but this has not been confirmed. In this study, which was conducted in Tokyo, Japan, from February to May 2005, we examined the possible causes of reduced bone mineral density (BMD) in male patients with schizophrenia.
METHOD: The BMD of the radius of 74 male patients (aged 31-78 years) who met the diagnostic criteria for DSM-IV schizophrenia was measured by dual-energy x-ray absorptiometry. Levels of prolactin (PRL), follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone, estradiol, and 1,25-dihydroxy vitamin D (VitD) were also measured. Pedometers were used to measure the impact of exercise.
RESULTS: Study subjects showed lower BMD in all age groups compared with reference values in healthy persons. There was no significant difference in the Z score among low, medium, and high exercise groups. 87% of the subjects had hyperprolactinemia, and VitD levels were normal in all subjects except 1. The high PRL group had lower levels of FSH and LH, and significantly lower levels of estradiol (p < .05), compared with the normal PRL group. In the high PRL group, there was a significant negative correlation between the duration of treatment and the Z score (p < .05).
CONCLUSION: Male patients with schizophrenia had lower BMD than normal individuals irrespective of the amount of exercise or the level of VitD. The results support the hypothesis that inhibition of the hypothalamo-pituitary-gonadal axis by hyperprolactinemia contributes to the mechanism of the bone loss and suggest that the longer the duration of hyperprolactinemia, the greater the reduction in BMD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18278991     DOI: 10.4088/jcp.v69n0307

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  29 in total

1.  A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.

Authors:  Chadi A Calarge; Bridget Zimmerman; Diqiong Xie; Samuel Kuperman; Janet A Schlechte
Journal:  J Clin Psychiatry       Date:  2010-03       Impact factor: 4.384

2.  Possible mechanisms for the skeletal effects of antipsychotics in children and adolescents.

Authors:  Chadi A Calarge; Stephanie D Ivins; Katherine J Motyl; Amal A Shibli-Rahhal; Michael M Bliziotes; Janet A Schlechte
Journal:  Ther Adv Psychopharmacol       Date:  2013-10

3.  Risk of hospitalization for hip fracture and pneumonia associated with antipsychotic prescribing in the elderly: a self-controlled case-series analysis in an Australian health care claims database.

Authors:  Nicole Pratt; Elizabeth E Roughead; Emmae Ramsay; Amy Salter; Philip Ryan
Journal:  Drug Saf       Date:  2011-07-01       Impact factor: 5.606

Review 4.  Osteoporosis and fracture risk in people with schizophrenia.

Authors:  Taishiro Kishimoto; Marc De Hert; Harold E Carlson; Peter Manu; Christoph U Correll
Journal:  Curr Opin Psychiatry       Date:  2012-09       Impact factor: 4.741

5.  Propranolol Attenuates Risperidone-Induced Trabecular Bone Loss in Female Mice.

Authors:  Katherine J Motyl; Victoria E DeMambro; Deborah Barlow; David Olshan; Kenichi Nagano; Roland Baron; Clifford J Rosen; Karen L Houseknecht
Journal:  Endocrinology       Date:  2015-04-08       Impact factor: 4.736

6.  Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain.

Authors:  Katherine J Motyl; Ingrid Dick-de-Paula; Ann E Maloney; Sutada Lotinun; Sheila Bornstein; Francisco J A de Paula; Roland Baron; Karen L Houseknecht; Clifford J Rosen
Journal:  Bone       Date:  2011-08-11       Impact factor: 4.398

7.  A novel role for dopamine signaling in the pathogenesis of bone loss from the atypical antipsychotic drug risperidone in female mice.

Authors:  Katherine J Motyl; Megan Beauchemin; Deborah Barlow; Phuong T Le; Kenichi Nagano; Annika Treyball; Anisha Contractor; Roland Baron; Clifford J Rosen; Karen L Houseknecht
Journal:  Bone       Date:  2017-07-06       Impact factor: 4.398

8.  Osteomalacia and vitamin D deficiency in a psychiatric rehabilitation unit: case report and survey.

Authors:  Rudolf N Cardinal; Carol A Gregory
Journal:  BMC Res Notes       Date:  2009-05-09

Review 9.  Brains, bones, and aging: psychotropic medications and bone health among older adults.

Authors:  Monique J Brown; Briana Mezuk
Journal:  Curr Osteoporos Rep       Date:  2012-12       Impact factor: 5.096

10.  Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment.

Authors:  Jeffrey R Bishop; Leah H Rubin; James L Reilly; Mani N Pavuluri; John A Sweeney
Journal:  Ther Adv Psychopharmacol       Date:  2012-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.